{
  "symbol": "GILD",
  "year": 2022,
  "Period": "Y2022",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1854,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.184
  },
  "top_positive": [
    {
      "sent": "2004 Equity Incentive Plan, amended and restated May 10, 2017 (14) 10.3* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (15) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.5* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (17) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (18) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021) (19) 10.8* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012) (20) 10.9* Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (20) 10.10* Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013) (21) 10.11* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018) (15) 10.12* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (22) 10.13* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2020) (15) 10.14* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (17) 10.15* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (18) 10.16* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021) (15) 10.17* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019) (17) 10.18* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (18) 10.19* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021) (14) 10.20* Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (15) 10.21* Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.22* Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (17)",
      "score": 0.9994
    },
    {
      "sent": "31 Equity Compensation Plan Information The following table provides certain information with respect to our equity compensation plans in effect as of December\u00a031, 2021: (in millions, except per share amounts) Number of Common Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (1) Weighted-average Exercise Price of Outstanding Options, Warrants and Rights (1) Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category (a) (b) (c) Equity compensation plans approved by security holders: 2004 Equity Incentive Plan (2) 15.2 $ 70.95 74.9 Employee Stock Purchase Plan (3) 5.1 Total equity compensation plans approved by security holders 15.2 $ 70.95 80.0 Equity compensation plans not approved by security holders (4) 1.6 $ 67.28 6.7 Total 16.8 $ 70.60 86.7 ______________________________________________________ (1) Does not take into account 22\u00a0million restricted stock units, performance share awards or units and phantom shares, which have no exercise price and were granted under our 2004 and 2018 Equity Incentive Plans.",
      "score": 0.9917
    },
    {
      "sent": "31 Equity Compensation Plan Information The following table provides certain information with respect to our equity compensation plans in effect as of December\u00a031, 2021: (in millions, except per share amounts) Number of Common Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (1) Weighted-average Exercise Price of Outstanding Options, Warrants and Rights (1) Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category (a) (b) (c) Equity compensation plans approved by security holders: 2004 Equity Incentive Plan (2) 15.2 $ 70.95 74.9 Employee Stock Purchase Plan (3) 5.1 Total equity compensation plans approved by security holders 15.2 $ 70.95 80.0 Equity compensation plans not approved by security holders (4) 1.6 $ 67.28 6.7 Total 16.8 $ 70.60 86.7 ______________________________________________________ (1) Does not take into account 22\u00a0million restricted stock units, performance share awards or units and phantom shares, which have no exercise price and were granted under our 2004 and 2018 Equity Incentive Plans.",
      "score": 0.9917
    }
  ],
  "top_negative": [
    {
      "sent": "Violations of fraud and abuse laws or anti-bribery laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal health care programs (including Medicare and Medicaid).",
      "score": -0.9393
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    }
  ],
  "forward_snippets": [
    "We intend to continue committing significant resources to internal R&D opportunities and external business development activity to drive innovation and growth of our business.",
    "The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties.",
    "In 2021, we continued to invest in and advance our R&D pipeline across our therapeutic areas.",
    "In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through acquisitions, in-licensing and strategic collaborations.",
    "We intend to continue committing significant resources to internal R&D opportunities and external business development activity to drive innovation and growth of our business."
  ]
}